PMD Device Solutions AB Stock

Equities

PMDS

SE0021513645

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 10:10:46 2024-05-20 am EDT 5-day change 1st Jan Change
7.2 SEK -2.04% Intraday chart for PMD Device Solutions AB -12.73% -34.90%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 49M 4.59M Sales 2025 * 77M 7.21M Capitalization 150M 14.05M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3 x
Net cash position 2024 * 3M 281K Net cash position 2025 * 119M 11.14M EV / Sales 2025 * 0.4 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 25
Yield 2024 *
-
Yield 2025 *
-
Free-Float 23.61%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on PMD Device Solutions AB

1 day-2.04%
1 week-12.73%
Current month-8.28%
1 month-16.76%
3 months-37.93%
More quotes
1 week
7.20
Extreme 7.2
8.40
1 month
6.20
Extreme 6.2
9.65
Current year
6.20
Extreme 6.2
112.64
1 year
6.20
Extreme 6.2
112.64
3 years
6.20
Extreme 6.2
112.64
5 years
6.20
Extreme 6.2
112.64
10 years
6.20
Extreme 6.2
112.64
More quotes
Date Price Change Volume
24-05-20 7.2 -2.04% 2,838
24-05-17 7.35 -2.00% 6,668
24-05-16 7.5 -5.66% 17,205
24-05-15 7.95 -2.45% 11,715
24-05-14 8.15 -1.21% 36,354

Delayed Quote Nasdaq Stockholm, May 20, 2024 at 10:10 am EDT

More quotes
PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.
Calendar
More about the company

Chiffre d''affaires - Rate of surprise

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW